UNSPSC 51101915: Benflumetol or lumefantrine

This classification denotes an antimalarial agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F38R0JR742. European Medicines Agency schedules Lumefantrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08618MIG. Lumefantrine generally arises in the molecular formula C30H32CL3NO.

The term LUMEFANTRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 1 1998, list 39.) LUMEFANTRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Benflumetol or lumefantrine bears US NLM identifiers UMLS ID C0531104 and NCI Concept Code C81541. SMILES: CLC1CC(C(O)CN(CCCC)CCCC)C2C(/C(=C/C3CCC(CL)CC3)C3C2CCC(CL)C3)C1.

UNSPSC 51101915 Benflumetol or lumefantrine, a Commodity code, shows minimal alignment with recent state and local procurement activity. The code nominally covers antimalarial pharmaceutical ingredients, but the recent opportunities tagged under it involve procurement of naloxone kits, emergency medical supplies, OTC products, and generic pharmaceuticals—none of which are benflumetol or lumefantrine formulations.

The recent activity reflects purchases by health departments, fire rescue divisions, and cooperative purchasing alliances seeking immediate-delivery medical consumables and broad-spectrum generic pharmaceuticals, not specialty antimalarial compounds. Seminole County, Florida issued an IFB in June 2026 for naloxone and drug deactivation systems with a July 26, 2023 deadline; the City of Tampa posted an IFB for medical and first aid supplies for the Fire Department Rescue Division with a March 13, 2026 deadline and an estimated contract value of $700,000.00, designated as a sheltered opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026 (deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon; and the Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer prescription fulfillment models outside traditional PBM channels. The code exhibits no recent procurement activity for benflumetol or lumefantrine specifically, and the opportunities currently attributed to it do not support market development under this commodity classification.